Research Context
Our Ipamorelin vial is a selective growth-hormone-releasing peptide supplied at >99% HPLC purity for endocrine and somatotropic research. Ipamorelin is frequently paired in community terminology with CJC-1295 — together referred to as the "CJC" stack.
Ipamorelin is a staple research compound among research peptides studied for clean GH-release profiles in endocrine models. Investigators routinely group these compounds with other GHRH analogs for axis-comparison studies.
A selective growth-hormone-releasing peptide investigated for its clean GH-release profile in endocrine models.
Ipamorelin: Selective Growth Hormone Secretagogue Research Peptide
Ipamorelin (often abbreviated as "Ipa" in research communities) is a synthetic pentapeptide and a selective growth hormone secretagogue (GHS). It functions as a ghrelin receptor agonist, specifically binding to the growth hormone secretagogue receptor type 1a (GHS-R1a) in the pituitary gland and hypothalamus to stimulate the release of growth hormone (GH). Ipamorelin is frequently referenced alongside specific dosage colloquialisms (such as Ipa-100, Ipa-200, or Ipa-300) to denote the microgram concentration being evaluated in a given research protocol.
What distinguishes Ipamorelin from other GHRPs is its remarkable selectivity. Research demonstrates Ipa stimulates GH release without significantly affecting cortisol, prolactin, or aldosterone levels, making it one of the "cleanest" GH secretagogues available for research. Unlike other GHRPs that also stimulate appetite through ghrelin receptor activation, Ipamorelin has minimal effects on hunger signaling, which is a key differentiator in comparative studies.
Ipamorelin is frequently researched in combination with Growth Hormone Releasing Hormone (GHRH) analogs such as CJC-1295 No DAC, Sermorelin, or Tesamorelin. This combination is studied for its synergistic effects on pulsatile GH release, as GHRPs and GHRH analogs operate through different but complementary signaling pathways in the somatotropic axis.
Ipamorelin Mechanism of Action: Selective GHS-R1a Agonism
Ipamorelin binds to the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor, which is expressed in the pituitary gland and hypothalamus. This binding mimics the action of endogenous ghrelin, triggering a signaling cascade that stimulates the synthesis and release of growth hormone from somatotroph cells in the anterior pituitary.
Unlike non-selective GHRPs, Ipa demonstrates high specificity for GH release without significant off-target effects. Research models show Ipamorelin does not substantially elevate cortisol (a stress hormone), prolactin (which can have anti-gonadal effects), or aldosterone (a mineralocorticoid). This selectivity makes Ipamorelin particularly valuable for research protocols (including Ipa-100, Ipa-200, and Ipa-300 dosing schemes) where minimizing stress-axis or reproductive-axis interference is critical.
Ipamorelin preserves the natural pulsatile pattern of GH secretion, which is essential for maintaining normal physiological function. Continuous or non-pulsatile GH elevation can lead to receptor desensitization and adverse effects, but Ipa's mechanism supports the body's natural rhythmic GH release patterns. This characteristic is frequently studied in aging research, where natural GH pulsatility declines with age.
Ipamorelin vs. GHRP-2 vs. GHRP-6: Comparative GHRP Research Analysis
Researchers frequently compare these three growth hormone releasing peptides to understand the trade-offs between GH release potency, selectivity, and side effect profiles. The table below summarizes how Ipa stacks up against GHRP-2 and GHRP-6 across the most-studied research parameters.
| Feature | Ipamorelin (Ipa) | GHRP-2 | GHRP-6 |
|---|---|---|---|
| Peptide Type | Pentapeptide (5 amino acids) | Hexapeptide (6 amino acids) | Hexapeptide (6 amino acids) |
| Receptor Target | GHS-R1a (ghrelin receptor) | GHS-R1a (ghrelin receptor) | GHS-R1a (ghrelin receptor) |
| GH Release Potency | Moderate | High | Very High |
| Selectivity | Highly selective (minimal cortisol/prolactin effects) | Moderately selective (some cortisol/prolactin elevation) | Non-selective (significant cortisol/prolactin elevation) |
| Appetite Stimulation | Minimal | Mild | Strong (potent ghrelin-mimetic) |
| Water Retention Risk | Low | Moderate | High |
| Primary Research Application | Clean GH elevation, aging research, combination protocols | Potent GH release, body composition studies | Maximum GH release, appetite research |
| Typical Research Dosing Scale | Micrograms (100-300 mcg) | Micrograms (100-300 mcg) | Micrograms (100-300 mcg) |
| Common Combinations | CJC-1295 No DAC, Sermorelin, Tesamorelin | CJC-1295 No DAC, Sermorelin | CJC-1295 No DAC (less common due to side effects) |
Note: While all three peptides stimulate GH release through ghrelin receptor activation, Ipamorelin is distinguished by its selectivity and minimal side effect profile. Researchers often combine GHRPs with GHRH analogs (such as CJC-1295 or Sermorelin) for synergistic effects. Formulation ratios and purity metrics may vary by batch.
Ipamorelin Chemical Specifications
| Specification | Value |
|---|---|
| Peptide Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| CAS Number | 170851-70-4 |
| Synonyms | Ipamorelin, Ipa, Growth Hormone Secretagogue |
| Molecular Formula | C₃₈H₄₉N₉O₅ |
| Molar Mass | 711.85 g/mol |
| Peptide Length | 5 amino acids (pentapeptide) |
| Purity | ≥99% by HPLC |
| Form | Lyophilized white powder |
Note: Formulation ratios and purity metrics may vary by batch. Always refer to the batch-specific Certificate of Analysis (COA) included with your order for exact composition and laboratory-verified specifications.
Storage and Stability
Lyophilized Ipamorelin should typically be stored at -20°C in a tightly sealed container, protected from light and moisture. Under these conditions, it generally remains stable for up to 24 months from the manufacture date.
Ipamorelin can typically be shipped at room temperature for short periods (up to two weeks) without significant degradation, making it suitable for standard shipping methods.
Once reconstituted with bacteriostatic water, the solution should be refrigerated at 2-8°C and typically used within 28 days. Researchers should avoid repeated freeze-thaw cycles and vigorous shaking to maintain peptide integrity.
Research Dosing Considerations
Ipamorelin is typically reconstituted with bacteriostatic water. Because it is dosed in microgram amounts in research models (commonly Ipa-100, Ipa-200, or Ipa-300 protocols), researchers typically use reconstitution volumes of 1-3mL to allow for precise measurement with insulin syringes. In research protocols, Ipamorelin is often administered subcutaneously, frequently in combination with GHRH analogs for synergistic GH release.
Investigators studying comprehensive endocrine or somatotropic protocols often research Ipa alongside GHRH analogs such as CJC-1295 No DAC, Sermorelin, or Tesamorelin. The combination of a GHRP (like Ipa) with a GHRH analog is studied for its ability to produce greater GH release than either compound alone, as they operate through different but complementary signaling pathways.
Ipamorelin Research FAQ
Q: What makes Ipamorelin different from GHRP-2 and GHRP-6?
A: Ipamorelin is highly selective, meaning it stimulates GH release without significantly affecting cortisol, prolactin, or aldosterone levels. GHRP-2 has moderate selectivity with some cortisol/prolactin elevation, while GHRP-6 is non-selective and significantly elevates both cortisol and prolactin. Additionally, Ipamorelin has minimal effects on appetite, while GHRP-6 is a potent ghrelin-mimetic that strongly stimulates hunger.
Q: Why is Ipamorelin often combined with CJC-1295 or Sermorelin?
A: Ipamorelin (a GHRP) and CJC-1295/Sermorelin (GHRH analogs) operate through different signaling pathways. GHRPs act on the ghrelin receptor to stimulate GH release, while GHRH analogs act on GHRH receptors. When combined, they produce a synergistic effect that results in greater GH release than either compound alone, a phenomenon well-documented in endocrine research.
Q: What are the common minor side effects observed in Ipamorelin research models?
A: In research studies, Ipamorelin is generally well-tolerated due to its selectivity. The most commonly reported effects are mild injection site reactions and occasional transient headache. Unlike other GHRPs, Ipamorelin typically does not cause significant water retention, increased appetite, or elevation of stress hormones.
Q: Can Ipamorelin be mixed with other research peptides?
A: It is generally recommended to reconstitute and evaluate Ipamorelin as a standalone compound. While researchers often administer Ipamorelin alongside GHRH analogs in their protocols, mixing them in the same vial prior to administration can lead to unpredictable chemical interactions. Researchers typically reconstitute them separately and administer them at the same time via separate injections.
Q: What is the typical Ipamorelin research dosing scale?
A: Ipamorelin is dosed in micrograms (mcg), with research protocols most commonly referencing 100, 200, or 300 mcg per administration (often termed Ipa-100, Ipa-200, Ipa-300). Lyophilized vials are typically reconstituted with 1–3 mL of bacteriostatic water to allow precise measurement with insulin syringes. All dosing references are derived from published preclinical literature and are provided for in vitro and animal-model protocol design only.
Q: How is Ipamorelin studied in muscle growth and recovery research?
A: Researchers investigate Ipamorelin's selective GH release profile in models examining lean tissue accretion, connective-tissue repair, and post-exercise recovery. Because Ipamorelin preserves the natural pulsatile pattern of GH secretion without elevating cortisol or prolactin, it is frequently used as a comparator in protocols evaluating IGF-1 downstream signaling and muscle-protein synthesis endpoints.
Related Products
Researchers studying Ipamorelin frequently reference the following hormonal and performance compounds in companion protocols:
Scientific References and Citations
- Raun K, et al. Ipamorelin, a novel growth hormone secretagogue. Eur J Endocrinol. 1998;138(5):552-559. doi:10.1530/eje.0.1380552
- Hansen TK, et al. Effects of growth hormone secretagogues on growth hormone release in vitro. Eur J Endocrinol. 2000;142(5):500-506. doi:10.1530/eje.0.1420500
- Malagón MM, et al. Different intracellular pathways are involved in growth hormone-releasing peptide-6 and growth hormone-releasing hormone action on rat anterior pituitary cells. Endocrinology. 1996;137(3):1097-1103. doi:10.1210/endo.137.3.8603615
- Arvat E, et al. Growth hormone-releasing peptides and their analogs: clinical perspectives. J Endocrinol Invest. 2000;23(6 Suppl):45-52.
- Ghigo E, et al. The endocrine effects of ipamorelin, a new synthetic GH-releasing peptide, in adults. J Clin Endocrinol Metab. 1999;84(10):3559-3565. doi:10.1210/jcem.84.10.6045
- Brogden RN, Fitton A. Ipamorelin. Drugs R D. 1999;1(4):315-320. doi:10.2165/00126839-199901040-00007